Raj Manchandani, MD
Hematology · Leesburg, VANPI 1639387384
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,040 of the $10,031 with a category attached, or 70.2%. 33 manufacturers reported payments, led by AstraZeneca at 56.5% of the total. 2025 is the largest year on record at $5,021, 5.1 times the $979 reported in 2019.
Across 126 payments — averaging $79.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Johnson & Johnson$2K
- Genentech USA, Inc.$230
- Fennec Pharmaceuticals, Inc.$198
- Amgen$183
- GSK$160
- plus $1K from 27 others
What the payments were for
- Consulting fees$7,04070%
- Travel & lodging$2653%
- Food & beverage$2,67127%
- Education$551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $5,668 |
| Johnson & Johnson(2 entities) | 30 | $2,336 |
| Genentech USA, Inc. | 12 | $230 |
| Fennec Pharmaceuticals, Inc. | 1 | $198 |
| Amgen | 9 | $183 |
| GSK | 1 | $160 |
| Bristol Myers Squibb | 6 | $118 |
| Intuitive Surgical | 1 | $116 |
| Novartis | 5 | $112 |
| Merck | 6 | $93 |
| EMD Serono, Inc. | 3 | $79 |
| Astellas Pharma US Inc | 5 | $73 |
| Seagen Inc. | 3 | $68 |
| Puma Biotechnology, Inc. | 3 | $61 |
| Lilly USA, LLC | 4 | $58 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Foundation Medicine, Inc. | 2 | $51 |
| Myriad Genetic Laboratories, Inc. | 2 | $45 |
| Pfizer | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 3 | $37 |
| Bayer | 2 | $29 |
| Immunogen, Inc. | 1 | $24 |
| Curonix LLC | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $22 |
| Sanofi | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,031 in reported general payments places this provider in the 70th percentile of 26 hematology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 25 | $385,783 |
| TagrissoOsimertinib Mesylate | 13 | $217,888 |
| Lenalidomide | 11 | $142,646 |
| EliquisApixaban | 96 | $108,241 |
| Abiraterone Acetate | 25 | $53,277 |
| Letrozole | 40 | $888 |
| Imatinib Mesylate | 12 | $884 |
| Lidocaine Hcl ViscousLidocaine Hcl | 23 | $488 |
| Anastrozole | 17 | $238 |
| Dexamethasone | 14 | $238 |
| Hydroxyurea | 23 | $235 |
| Prochlorperazine Maleate | 16 | $162 |
| Prednisone | 27 | $138 |
| Ondansetron Hcl | 11 | $129 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $58 | $385,78325 claims |
| AstraZenecaTagrisso | $5,668 | $217,88813 claims |
| PfizerEliquis | $45 | $108,24196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 26 hematology providers in Virginia.
Other hematology in Leesburg
- Hillary MaitlandCharlottesville$440K
- Barbara MacikCharlottesville$90K
- Emily AyersCharlottesville$63K
- Stephen MedlinFairfax$50K
- Laahn FosterCharlottesville$35K
- Michael KengCharlottesville$15K
- Indumathy VaradarajanCharlottesville$12K
- Ruchi DesaiRichmond$9K
- Germame AjeboFairfax$7K
- Daniel ReedCharlottesville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.